Loading organizations...
Loading organizations...
Pioneering active specific immunotherapies for autoimmune diseases.
Imcyse has raised $64.6M across 2 funding rounds.
Imcyse has raised $64.6M in total across 2 funding rounds.
Imcyse has raised $64.6M in total across 2 funding rounds.
Imcyse's investors include Biogenosis, Epimede, KU Leuven, LSP, Noshaq, Pfizer, SFPI-FPIM, SRIW, Belfius, DGO6, Marc Moles le Bailly, Paul Van Dun.
Imcyse has raised $64.6M across 2 funding rounds. Most recently, it raised $25.8M Series B Extension in February 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 17, 2021 | $25.8M Series B Extension | Biogenosis, Epimede, KU Leuven, LSP, Noshaq, Pfizer, SFPI-FPIM, SRIW | |
| Jun 18, 2019 | $38.8M Debt / Grant / Series B | LSP | Belfius, Biogenosis, DGO6, Marc Moles le Bailly, Paul Van Dun, Marc Foidart, Fontaine François, Franssen Christina |